Literature DB >> 8412300

Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice.

A Kawata1, T Han, B Dadey, H U Weier, M Okazaki, S Yokota, T Fukiage, H Xiao, A M Block, M Barcos.   

Abstract

A new cell line, designated MO1043, was established from the peripheral blood (PB) of a patient with B-cell chronic lymphocytic leukemia (CLL). Both the PB leukemia cells and MO1043 were found to have an abnormal cytogenetic marker of trisomy 12, the most common cytogenetic abnormality in CLL. In addition, both the PB cells and MO1043 expressed a cell surface phenotype of typical B-CLLs. The MO1043 was efficiently transplanted into X-irradiated athymic nude mice by i.p. inoculation after it was subjected to serial passages in new born (1 week old) and irradiated adult nude mice. The tumor of a CLL cell line (termed CLL tumor) was also generated in the nude mice by s.c. inoculation of the cells. The MO1043 was inoculated i.p. into mice with severe combined immunodeficiency (SCID) which had not been subject to any preconditionings. The CLL tumor in the non-conditioned SCID mice was disseminated to various tissues in a manner more analogous to CLL tumors in patients as compared with nude mice, where the CLL tumors were not as widely disseminated. At each of four different tumor doses, i.e. 2 x 10(6), 6 x 10(6), 1.8 x 10(7) and 5.4 +/- 10(7) cells of MO1043, the transplantability was 100%. Titration experiments revealed a reciprocal relationship between survival and the number of tumor cells inoculated. FACS analysis showed that several cell surface markers of the parental MO1043 were maintained in CLL tumors from nude and SCID mice. Fluorescence in situ hybridization with novel DNA probes demonstrated that CLL tumors of both nude and SCID mice maintained trisomy 12. The CLL tumor models developed here, particularly the SCID mouse model, may be very useful for therapeutic studies of CLL.

Entities:  

Mesh:

Year:  1993        PMID: 8412300     DOI: 10.1016/0145-2126(93)90154-d

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model.

Authors:  Deepti Chadalavada; Trinka W Adamson; John C Burnett; Robert W Chen; John J Rossi
Journal:  Comp Med       Date:  2014-06       Impact factor: 0.982

2.  Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia.

Authors:  Giulia Fabbri; Antony B Holmes; Mara Viganotti; Claudio Scuoppo; Laura Belver; Daniel Herranz; Xiao-Jie Yan; Yasmine Kieso; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Adolfo A Ferrando; Riccardo Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-17       Impact factor: 11.205

3.  Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.

Authors:  Erin Hertlein; Kyle A Beckwith; Gerard Lozanski; Timothy L Chen; William H Towns; Amy J Johnson; Amy Lehman; Amy S Ruppert; Brad Bolon; Leslie Andritsos; Arletta Lozanski; Laura Rassenti; Weiqiang Zhao; Tiina M Jarvinen; Leigha Senter; Carlo M Croce; David E Symer; Albert de la Chapelle; Nyla A Heerema; John C Byrd
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

4.  MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Authors:  Masato Ito; Shinsuke Iida; Hiroshi Inagaki; Kazuya Tsuboi; Hirokazu Komatsu; Motoko Yamaguchi; Naoya Nakamura; Ritsuro Suzuki; Masao Seto; Shigeo Nakamura; Yasuo Morishima; Ryuzo Ueda
Journal:  Jpn J Cancer Res       Date:  2002-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.